Milan, Italy

PierFranco Spano

This inventor holds 1 USPTO granted patent. Top assignees: Applied Research Systems Ars Holding N.v., Yeda Research and Develpment & Co. Ltd. Active years: 2007.


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: PierFranco Spano: Innovator in Neurodegenerative Disease Treatment

Introduction

PierFranco Spano is a notable inventor based in Milan, Italy. He has made significant contributions to the field of neurodegenerative diseases through his innovative research and patents. His work focuses on the treatment and prevention of neurological disorders, showcasing his dedication to improving human health.

Latest Patents

One of PierFranco Spano's key patents is the IL6RIL6 chimera for the treatment of neurodegenerative diseases. This invention relates to the use of the IL6RIL6 chimera in addressing various neurological diseases and disorders. With 1 patent to his name, Spano's work is a testament to his expertise and commitment to advancing medical science.

Career Highlights

Throughout his career, PierFranco Spano has worked with esteemed organizations such as Yeda Research and Development Co. Ltd. and Applied Research Systems Ars Holding N.V. His experience in these companies has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

PierFranco Spano has collaborated with notable individuals, including Michel Revel and Judith Chebath. These partnerships have enriched his research and expanded the impact of his inventions in the scientific community.

Conclusion

In summary, PierFranco Spano is a distinguished inventor whose work in neurodegenerative disease treatment has the potential to make a significant impact on healthcare. His innovative approach and dedication to research continue to inspire advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…